Integrating Emerging Evidence in Adjunctive Therapies into Team-Based Management Strategies in Type 1 Diabetes

Integrating Emerging Evidence in Adjunctive Therapies into Team-Based Management Strategies in Type 1 Diabetes

On-Demand Webcast

Robert R. Henry, MD, FRCP(C), FRCE, FACE, FACN
Professor of Medicine
University of California, San Diego
Chief, Section of Endocrinology, Metabolism & Diabetes
Director, Center for Metabolic Research
Veterans Affairs Healthcare System
San Diego, California

Intended Learners

This activity is designed for endocrinologists, internists, hospitalists, as well as the entire multidisciplinary team of residents, fellows, NPs, PAs, nurses, pharmacists, and other hospital-based healthcare professionals who frequently manage patients with T1D.

Learning Objectives

After completing this activity, participants should be able to:

  • Recognize the negative clinical and socioeconomic impact of poor glycemic control and the barriers to achieving recommended levels of HbA1c in patients with T1DM
  • Evaluate the efforts to achieve glycemic control using available anti-hyperglycemic agents as adjunct to insulin therapy in T1DM
  • Describe the latest clinical data surrounding the efficacy, safety, mechanism of action, and benefits/limitations of current and emerging SGLT inhibitors in T1DM
  • Develop multidisciplinary care strategies that consider the role of SGLT inhibitors as adjunct to insulin therapy for patients with T1DM
Activity Overview

This on-demand webcast is available with synchronized slides and video. 

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at, participants may immediately print their documentation of credit.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring webcast.

Release date:September 27, 2018
Expiration date: September 27, 2019
Estimated time to complete: 1 hour

There is no fee associated with this activity.

For questions regarding this educational activity, please call 609-371-1137.

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to


Jointly Accredited ProviderIn support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


NACCME designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This continuing nursing education activity awards 1 contact hour.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.0 contact hour.


This activity is approved for 1.0 contact hour (0.1 CEU) of continuing pharmacy education (UAN JA0006201-0000-18-200-H01-P).

This educational activity is a knowledge-based activity.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Senior Manager, Accreditation and Compliance, NACCME, in writing at 104 Windsor Center Drive, Suite 200, East Windsor, NJ 08520. The Senior Manager, Accreditation and Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises Robert R. Henry, MD, FCRP(C); and Donna Brophy, Amy Ghiretti, Jennifer Ilcyn, Mary Johnson, Susan Kahn, Randy Robbin, Margaret Stefan, and Susan Yarbrough, NACCME.

Independent clinical reviewer: Lorena A. Wright, MD, Clinical Assistant Professor, Metabolism, Endocrinology, and Nutrition, University of Washington Medical Center/Roosevelt Harborview Medical Center, Seattle, Washington

Nurse planner: Susie Seaman, NP, Sharp Rees-Stealy Wound Clinic, San Diego, California

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Henry: Research – AstraReal, Eli Lilly, Hitachi, Lexicon, Novo Nordisk, Viacyte; Consultant – Abbott, AstraZeneca, Boehringer Ingelheim, Intarcia, Ionis, Johnson & Johnson, Janssen, Lexicon, Merck, Sanofi Aventis; Advisory Board – Abbott, AstraZeneca, Boehringer Ingelheim, Elcelyx, Intarcia, Johnson & Johnson, Janssen, Merck, Sanofi Aventi, Servier
Ms. Seaman: Advisory Board - Mölnlycke

Dr. Wright has disclosed no relevant financial relationships with any commercial interests.

Ms. Brophy, Ms. Ghiretti, Ms. Ilcyn, Ms. Johnson, Ms. Kahn, Mr. Robbin, Ms. Stefan, and Ms. Yarbrough have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty has disclosed that no off-label/unapproved uses of drugs and/or devices will be discussed.

Grant Support

Supported by an educational grant from Sanofi US and Lexicon Pharmaceuticals, Inc.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.
NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2018 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.